Mode
Text Size
Log in / Sign up
N/A N=1,485 Randomized Single-blind Health Services Research

Effect of a Patient-Centered Decision App on TOLAC

Pregnancy · Repeat Cesarean Section · Vaginal Births After Cesarean

Enrolled (actual)
1,485
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Number of Participants Who Underwent a Trial of Labor After Cesarean (TOLAC) Delivery — 315; 338 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Prior CD Decision App (Behavioral)
Age
Adult, Older Adult · 18+ yrs
Sex
Female
Sponsor
University of California, San Francisco
Primary completion
Jun 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Who Underwent a Trial of Labor After Cesarean (TOLAC) Delivery
315; 338
SECONDARY
Number of Participants Who Underwent Vaginal Birth After Cesarean (VBAC)
231; 233
SECONDARY
Knowledge About TOLAC and ERCD
5.0; 5.0
SECONDARY
Decisional Conflict
17.2; 17.5
SECONDARY
Shared Decision Making
74.4; 74.8
SECONDARY
Decision Self-Efficacy
90.7; 90.3
SECONDARY
Decision Satisfaction
4.62; 4.65
SECONDARY
Maternal Major Morbidity
19; 23
SECONDARY
Maternal Minor Morbidity
36; 36
SECONDARY
3rd or 4th Degree Lacerations
16; 12
SECONDARY
Perinatal Death or Hypoxic-ischemic Encephalopathy
2; 0; 4; 0; 2; 4
SECONDARY
Neonatal Respiratory Morbidity
67; 68
SECONDARY
Neonatal Intensive Care Unit (NICU) Admission
98; 87

Summary

Cesarean delivery (CD) is the most common inpatient surgery in the US, accounting for nearly one third of births annually. In the last decade, the CD rate has increased by approximately 50%, with almost 1.3 million procedures performed in 2012 (Hamilton 2013). CDs have been associated with an increase in major maternal morbidity (Silver 2010), with corresponding increases in length of inpatient care following delivery and frequency of hospital readmission (Lydon-Rochelle 2000). Organizations including Healthy People, the American College of Obstetricians and Gynecologists (ACOG), and the American College of Nurse Midwives have targeted reducing the CD rate as an important public health goal for more than a decade; however, identifying interventions to achieve this goal has proven challenging. Repeat CDs are a significant contributor to the increased cesarean rate, resulting from the combination of a rising rate of primary CD and a decreasing rate of vaginal birth after cesarean (VBAC), which declined from a high of 28.3% in 1996 (Guide 2010) to 9.2% in 2010 (Hamilton 2011). Why the VBAC rate has decreased so dramatically remains a subject of debate; the extent to which these changes are driven by patient preferences is not known. An NIH consensus conference statement noted that "the informed consent process for TOLAC and Elective Repeat Cesarean Delivery (ERCD) should be evidence-based, minimize bias, and incorporate a strong emphasis on the values and preferences of pregnant women," and recommended "interprofessional collaboration to refine, validate, and implement decision-making and risk assessment tools" to accomplish that goal (Cunningham 2010). Our group recently created a decision tool, which we refer to as the Prior CD App (PCDA), to help English- or Spanish-speaking TOLAC-eligible women delivering at hospitals that offer TOLAC consider individualized risk assessments, incorporate their values and preferences, and participate in a shared decision making process with their providers to make informed decisions about delivery approach. We are now conducting a randomized study of the effect of a Prior CD App on TOLAC and VBAC rates, as well as a number of aspects of decision quality.

Eligibility Criteria

Inclusion Criteria

  • Women with exactly one prior Cesarean Delivery.
  • Current singleton pregnancy.
  • Gestational age, 12-24 weeks.
  • English or Spanish speaker.
  • Must be receiving prenatal care at one of the participating centers.

Exclusion Criteria

  • Contraindications to vaginal delivery (e.g., placenta previa, prior classical cesarean, previous uterine rupture).
  • Prior VBAC.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02646423). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search